The high renal uptake of radiolabeled somatostatin analogs is dose limiting. Lowering this
uptake permits higher radioactivity doses and, thus, tumor doses to be administered. We …

During tumor therapy with radiolabeled somatostatin analogs, the kidneys are dose limiting.
Renal uptake in patients can effectively be reduced by a 4-to 10-h intravenous infusion of a …

Purpose Renal irradiation is a dose-limiting factor in peptide receptor radionuclide therapy
using radiolabelled somatostatin analogues. This irradiation is mainly caused by …

The characteristics of terbium-161 diethylene triamine penta-acetic acid (DTPA) labelled
octreotide with respect to specific binding to somatostatin (octreotide) receptors on rat brain …

In vitro octreotide receptor binding of [111 In-DOTA 0, d-Phe 1, Tyr 3] octreotide (111 In-
DOTATOC) and the in vivo metabolism of 90 Y or 111 In-labelled DOTATOC were …

In peptide receptor radionuclide therapy (PRRT) using somatostatin analogs labeled with β-
emitters, the radiosensitive kidney is the dose-limiting organ, because of high uptake and …

The somatostatin analogue [DOTA 0, Tyr 3] octreotate has a nine-fold higher affinity for the
somatostatin receptor subtype 2 as compared with [DOTA 0, Tyr 3] octreotide. Also, labelled …

We evaluated the following 111In-labeled somatostatin (SS) analogues (
diethylenetriaminepentaacetic acid, DTPA; tetraazacyclododecanetetraacetic acid …

As scintigraphy with [111 In-DTPA 0] octreotide has become a standard technique in
analysing somatostatin receptor-receptor positive lesions such as neuroendocrine tumours …

Purpose Radiolabelled somatostatin analogues, such as octreotide and octreotate, are used
for tumour scintigraphy and radionuclide therapy. The kidney is the most important critical …